Doctor Evidence to Deploy Its AI-Enabled SaaS DOC Search™ and DOC Analytics™ Platform for COVID-19 to Accelerate Drug Discovery

July 14, 2020 10:00 AM Eastern Daylight Time

SANTA MONICA, Calif.–(BUSINESS WIRE)–Doctor Evidence (“DRE”) has developed new tools for automated network meta-analysis, to now be used in the hunt for the most effective treatments for COVID-19. Clinical trial data is continuously emerging that can now be aggregated in real time using DRE’s DOC Analytics™ platform.

Based on the World Health Organization’s International Clinical Trials Registry Platform (WHO ICTRP), as of July 12th there are some 1,798 COVID-19 treatment trials ongoing globally. Preliminary results and data from high-profile trials are now available, including for Remdesivir, Dexamethasone, and Hydroxychloroquine. DRE is using its first-in-industry DOC Analytics™ platform to generate real-time network meta-analysis for researchers to produce quantitative analysis for any therapeutic question in the global landscape. This approach will inform decision makers with regard to real-time updates from clinical trials for quantitative comparison, analysis, and reporting on relevant outcomes.

This novel quantitative analytic approach leverages DRE’s open DOC Search™ platform for COVID-19, which makes available annotated set of literature from CORD19, the open research dataset made available by the Allen Institute et al. in response to the White House Task Force call to action in late March. DOC Search™ provides the foundation of medical conceptual organization to identify which key concepts are being reported across literature and trials. This platform continues to be available to research groups at https://covid19.doctorevidence.com/.

“We are breaking new ground in AI-assisted technology at a critical time for healthcare,” says Bob Battista, MBA, FRCPH, FRCP Edin., Co-founder and Chief Executive Officer of DRE. “Our industry-first automated network meta-analysis technology and AI-enabled search engine are being utilized for rapid assessment of drug candidates for COVID-19. DOC Search™ and Analytics™ are being used as a foundational tool by top 10 industry ranked global pharmaceutical/life science companies that are DRE clients.”

About DRE:

DRE is a market leading Software-as-a-Service (“SaaS”) company in the AI-enabled health technology marketplace that deploys state-of-the-art solutions to identify, synthesize, and analyze complex clinical data into actionable knowledge. DRE provides instant, continuous search and data synthesis intelligence across critical functions of Pharmaceutical, Biotech, Life Sciences and Medical Technology companies to optimize their strategies that enable them to generate actionable data insights. DRE’s technology platform provides its customers with the DOC Analytics™ Insights Engine which empowers them to make better decisions from lab to patient.

Contacts

Toby Sayre
linkedin.com/in/toby-sayre-89ba904
pr@doctorevidence.com
+1 (310) 595-1265

Doctor Evidence’s newly released DOC Analytics™ performs rapid network meta-analyses to generate real-time insights using natural language processing and rigorous methodology

DRE offers clients a Center of Excellence with its AI-enabled SaaS platform including DOC Label™, DOC Search™ and DOC Analytics™

SANTA MONICA, Calif., May 19, 2020 /PRNewswire/ — Doctor Evidence (DRE), a leading Artificial Intelligence-powered SaaS healthcare insights company, has launched its revolutionary DOC (“Digital Outcome Conversion”) Analytics™ platform. DOC Analytics™ is a culmination of over 10-years of R&D and product development.  In DOC Analytics™, users can ask natural language medical questions and get precise search results that are powered by DRE’s DOC Search™ advanced AI search platform.  DOC Analytics™ then processes these search results directly into DOC Analytics™ statistical analysis engine, which generates fully transparent meta and network meta-analysis that are regulatory-grade analyses using the appropriate R statistical package.

DOC Analytics™ incorporates comprehensive methodological rigor that meets or exceeds the practice standards laid out in the Cochrane Manual for Systematic Reviews and other top global academic standards for evidence analysis. Since founding, DRE has pursued the vision of systematizing Evidence-Based Medicine (EBM) methodologies into a transparent SaaS  platform to accelerate medical insights. These insights can be translated into actionable strategies for R&D, drug discovery and product life cycle management for the  pharmaceutical (biotech and life sciences), medical guideline societies, payors, providers and medical technology markets.

DOC Analytics is an incredibly powerful and unique platform which allows you to rapidly extract and analyze the totality of scientific evidence to derive rigorous data-driven insights within minutes. We have never had this analytic speed and agility at our fingertips. Using DOC Analytics, we can quickly evaluate scientific hypotheses, explore therapeutic responses across sub-populations and assess the comparative impact of drugs in a very dynamic manner,” said Ameet Nathwani, MD, a senior pharmaceutical executive.  “Whether we’re looking for distinctive insights to accelerate the discovery and development of new drugs or informing payor negotiations using the most up to date evidence, DOC Analytics is a potential game-changer.”  

DOC Analytics is intended to elevate the work of scientists, clinical investigators, researchers, policymakers, guideline societies and academics for more precise and nuanced insights of data for scientific analysis and drug discovery,” said Bob Battista, FRCP Edin., Chief Executive Officer of DRE.  “It stands on the shoulders of many years of working with top experts and over 1-million ‘Gladwellian’ institutional hours of knowledge in EBM and rigorous methodologies. We are excited to have broken down the barriers and friction confronting researchers with our AI-enabled solutions that have been built on the large, proprietary training data sets from our years of methodical data curation.”

DRE currently serves 18 of the top 20 global pharmaceutical companies with its SaaS platform suite offerings.  The combined DRE SaaS suite of DOC Label, Search™ and Analytics™ offer a critical end-to-end solutions platform from therapy indication management to fit-to-purpose market value messages for key constituents in the healthcare ecosystem.  Upon its immediate release, DOC Analytics™ has been adopted by a top 5 global pharmaceutical company to be integrated into its DRE DOC suite and immediate use for its rapid analysis of COVID-19 data.   

About DRE:
DRE is a market leading company in the AI-enabled health technology marketplace that deploys state-of-the-art solutions to identify, synthesize, and analyze complex clinical data into actionable knowledge. DRE provides instant, continuous search and data synthesis intelligence across critical functions of Pharmaceutical, Biotech, Life Sciences and Medical Technology companies to optimize their strategies that enable them to generate actionable data insights. Its technology platform provides DRE’s customers with a Software-as-a-Service (“SaaS”) Insights Engine which empower them to make better decisions from lab to patient.

Contact:
Laura Guild
pr@doctorevidence.com
+1 (310) 595-1265

SOURCE Doctor Evidence

Related Links

http://www.doctorevidence.com

Doctor Evidence is Empowering Researchers with an Intuitive AI Solution for Rapid Literature Review and Surveillance – Updates to a User-Friendly Interface in DOC Search

SANTA MONICA, Calif., June 19, 2019 /PRNewswire/ –Doctor Evidence, a global health technology and consulting company in biomedical research, releases new updates and an interactive user interface for the DOC Search platform on June 24th.

DOC Search was designed to empower both novice and experienced researchers with a user-friendly turnkey solution to independently conduct rapid literature reviews and monitor for updates. Traditional searches can be inefficient and error-prone, involving blindly searching PubMed, manually reviewing the results, iteratively building out complex search strategies, and then translating those strategies for use in other databases. Comprehensiveness depends on deep domain knowledge, along with training to structure the query appropriately for each topic and database.

Doctor Evidence reinvented this process, enabling simple and rapid exploration of relevant topic areas across large bodies of evidence to distill meaningful insights with increased precision. DOC Search draws upon a biomedical research database of 31+ million publications, trials, congress abstracts, news articles, and more – powered by a robust ontology system incorporating all major clinical taxonomies, thus automatically employing all possible synonyms to ensure comprehensive retrieval.

The intuitive new User Interface (UI) makes advanced Artificial Intelligence (AI) and Natural Language Processing (NLP) technology more accessible. Combining powerful AI and NLP within this streamlined interface, DOC Search’s interactive data visualization tools reveal trends and evidence distributions. The technology has been trained to instantly classify randomized controlled trials, extract key information (such as geographic location and most published authors), and the newest machine learning algorithm identifies which studies are based on real-world evidence.

The automated term index identifies the most frequently occurring demographics, interventions, and outcomes reported in a defined set of search results. This powers the new Co-occurrences Matrix to populate a table representing the number of studies addressing frequently occurring patient characteristics by outcomes or interventions, or any selected comparison of these options. Among the uses for this interactive matrix are the following:

  • To assess safety profiles across a set of chosen interventions,
  • Determine the frequency of real-world data sources or study methods,
  • Locate head-to-head treatment comparisons, and
  • Assess the feasibility of an Indirect Treatment Comparison.

Users can also create personalized dashboards for immediate snapshot reports, identifying the most relevant and current insights across a large body of evidence. They can engage with the data by clicking on interesting trends, resulting in the custom widgets dynamically updating for the revised set of results. Meanwhile, DOC Search refines the search strategy throughout the exploratory process, which can be saved for personal email alerts or collaborative surveillance.

“DOC Search is the culmination of 15 years of software development,” stated Robert Battista, MBA, FRSPH, FRCP Edin., “adding to a growing technology stack that is revolutionizing the evidence synthesis space. Our new DOC Search empowers researchers and industry leaders to independently conduct rigorous rapid assessments, identify novel thought leaders, scope out new business needs, and monitor customized surveillance feeds with increased precision.”

About Doctor Evidence:
Doctor Evidence (DRE) is a health technology and consulting company utilizing state-of-the-art solutions that identify, synthesize, and analyze complex clinical research data into fit-to-purpose actionable knowledge. Resulting high quality evidence reviews provide guideline developers, academic researchers, medical providers, manufacturers, payers, and patients with evidence-based information to make timely and educated decisions on recommended treatment protocols, outcomes research, health economics, risk management, market access, reimbursement, value determinations, and burden of illness cost models. These methodologically rigorous reviews and analyses fully comply with accepted international standards to address the needs of patients, providers, and scientists worldwide. 

To learn more about DOC Search and Doctor Evidence, visit www.drevidence.com and www.GROWTHevidence.com.

SOURCE Doctor Evidence

Related Links

http://www.doctorevidence.com

Physicians Who Research & Refer Patients to Nationally Ranked Surgeons (Database Subscription Score) Use EBM Outcome Data Scores

Outcomes-based scoring is quite complex. The data on readmissions and patient mortality inside a hospital require no subjective interpretation, the data on complications however, is not as clearly documented. This is due to recording complications that require individual judgment. Coders, healthcare professionals and their patients may differ in their interpretation of events. As a result, complications may be recorded differently across facilities (or even by different coders within the same facility). Furthermore, even if codings were consistent, the codes themselves do not always separate a mild complication (like a simple infection) from a serious one that requires greater medical attention (like sepsis). Therefore, a time-tested, peer-reviewed methodology to account for complications must be integrated into Surgery Quality Scores.

NATIONAL NEWS: CMT Official Statement, “Support For Use of Whole Genome Sequencing in Concierge Medicine”

Editor-In-Chief, Michael Tetreault, Author
Editor-In-Chief, Michael Tetreault, Author

“If I were to ask you to describe how you picture your life in ten years, chances are you could paint a fairly clear picture,” says Tetreault. “DNA data with the continuous interaction and direction of a [Concierge] physician ushers in a healthcare utopia. In this way, it simplifies decision making using data, not practice.”

ATLANTA, GA | FEBRUARY 1, 2017 – Concierge Medicine Today issued a statement of support, noting, “Genetic technology has reached the point where the cost of conducting comprehensive genetic testing [ie. Whole Genome Sequencing] for hundreds of preventable diseases at a single time is now affordable,” said Catherine Sykes, CEO and Publisher of the national trade publication. “After years of thoughtful consideration, careful research and review, countless hours of dialogue with various physicians and technology companies, we encourage Concierge Medicine Physicians to make personal genomic data information available to patients so that they can start to understand their makeup, learn more about their individual genome and predictors, and begin to use these insights to improve their lives.”

Genetics usually refers to the study of individual genes and their role in disease or inheritance. Genomics refers to an individual’s entire genomic make-up. Genomics looks at the genetic sequence of genes, and their structure and function as well as the interactions between genes. An easy way to think about genetic testing is to compare it to a book, because genetics is truly our Instruction Manual of Life and genetic testing is simply a way to proofread each person’s Instruction Manual for potential typos, according to Sequencing.com.

The accuracy of whole genome sequencing is quickly improving and the cost is quickly dropping. Within the next couple of years, this technology will most likely be widely used by Concierge Physicians in the daily clinical care of their patients.

The Concierge Medicine Physician can, should [and currently is] acting as the informed fiduciary, shepherding the patient treatment process so as to make informed decisions with actionable data, together, with their patients. Advanced DNA research and whole genome sequencing have powerful applications, says trade publication, Concierge Medicine Today. Companies see Concierge Physicians as the ideal delivery model, allowing people to learn more about their DNA and make informed, data-driven decisions under the direction and support of their involved [Concierge] physician, to live a healthier life.

Brandon Colby, MD, is a world leader in the field of Predictive Medicine, a groundbreaking medical specialty that combines comprehensive genetic testing with personalized prevention based upon your genes. Colby specializes in Personal Genomics and Anti-aging / Age Management Medicine and invented genetic technologies to personalize services and products to an individual's genes. He is the Founder and CEO of Sequencing.com and a good friend of Concierge Medicine Today.
Brandon Colby, MD, is a world leader in the field of Predictive Medicine, a groundbreaking medical specialty that combines comprehensive genetic testing with personalized prevention based upon your genes. Colby specializes in Personal Genomics and Anti-aging / Age Management Medicine and invented genetic technologies to personalize services and products to an individual’s genes. He is the Founder and CEO of Sequencing.com and a good friend of Concierge Medicine Today.

“The genetic revolution has already begun, and it is having far-reaching effects on healthcare right now,” said Brandon Colby, MD and author of Outsmart Your Genes. “Our knowledge of how to use this information is increasing at an exponential rate. What this means is that we can now start to integrate genetics into our everyday lives. With comprehensive genetic testing, we launch an innovative strategy against disease, attacking it before it even manifests. Genetic testing, therefore, provides a new counter-offensive in our war against Alzheimer’s, cancer, heart disease, and many other diseases that have plagued our civilization for centuries. This is the most exciting, and potentially groundbreaking, medical development of this century.”

“The data, however, should be owned by the patient. Their Physician can help direct them on how to apply the information contained in WGS to maximize its benefits,” states Michael Tetreault, Editor of Concierge Medicine Today. “Patients need the ability to securely store, use, and understand genetic data.”

Concierge Medicine Today advises this should be accomplished through physician involvement and technology that integrates genetic data into software applications [apps]. Software apps are now available that analyze genetic data and transform the data into actionable information that can have a real impact on health.

Colby notes, whole genome sequencing allows him to “cast a wide net” by generating a tremendous amount of genetic data. He then uses apps at Sequencing.com that analyze the data and provide straightforward reports focused on relevant, actionable findings. He also noted that there are five questions you [patients and physicians] need to ask in order to assess the quality of the outcomes data: (1)  The credibility of the laboratory doing the testing; (2)  What types of diseases are included in the test; (3)  How thoroughly does the test actually evaluate risk for each of the diseases; (4)  Whether the information is provided in a way that makes it actionable; and (5)  Will the results be delivered in a format that is straightforward and easy to understand?

At the Louisville Innovation Summit (October 2015), former White House CTO, Aneesh Chopra outlined his vision for a future of healthcare managed by “information fiduciaries.”

“We are essentially undergoing the most entrepreneurial period in healthcare history,” Aneesh Chopra told the crowd at the Louisville Innovation Summit. In his keynote speech, From Innovation to Integration: Understanding the interdependence on people and data, Chopra presented his vision of the future of healthcare. That future, Chopra explained, is dependent on the careful management and integration of data into patient care. Chopra envisions a future where “each and every one of is given a valet key to their data.” The valet key, Chopra said, is not unlike how Netflix determines your user preferences. These valet keys can be distributed to patients. “They can be handed to an entity that the patient trusts to organize and manage their healthcare.

The third piece of the future of healthcare, Chopra said, is about managing options. He envisions a system where patients will have advisors, acting in their interests, to help them figure out their best plan. “I see the rise of an entirely new job description that doesn’t exist in health care,” Chopra said. With all the choice we have, we will need what he calls an “information fiduciary”—a person to entrust our data with, who can offer help making smarter decisions. “Which plan should I choose? Which primary care doctor?” asked Chopra. “What’s missing today from our delivery system is this muscle of being able to interpret and organize and advise individuals. We need someone to connect the dots.” [1]

Within a couple of years, Concierge Medicine Today understands genome sequencing will most likely be widely used by [Concierge] physicians in the daily clinical care of their patients. Currently available in academic medical centers, this advanced healthcare decision support tool provides the ability to predict and prevent disease and, if disease manifests, personalized therapies tailored to each patient. Due to decreasing costs and better understanding about how this information can be made actionable, this technology is now accessible to Concierge physicians.

“If I were to ask you to describe how you picture your life in ten years, chances are you could paint a fairly clear picture,” says Tetreault. “DNA data with the continuous interaction and direction of a [Concierge] physician ushers in a healthcare utopia. In this way, it simplifies decision making using data, not practice.”

J. Catherine Sykes serves as the CEO/Publisher of Concierge Medicine Today (CMT)
J. Catherine Sykes serves as the CEO/Publisher of Concierge Medicine Today (CMT)

“Anything that moves us toward the realization of better outcomes using data and evidence-based medicine gets a green light by Concierge Medicine Today” says Publisher, Catherine Sykes. “Whole Genome Sequencing used by Concierge Doctors empowers them to move purposefully in a predetermined direction on behalf of their patients. Our observation is that physicians and patients without clear vision are easily distracted. They have a tendency to drift from one ailment, prescription, problem or activity, to another. Without Concierge Physicians at the helm, there is no relational, financial, or data-driven compass that will appropriately impact a person’s life. Consequently, Physician surveys are finding that they are often making insurance-based decisions almost entirely on a patient’s insurance plan coverage (56%), decisions which can rob patients of their health, lifestyle and dreams.”

“What would happen if a physician were to begin speaking to a patient’s future potential rather than their past performance?” adds Colby. “Where the practice of medicine may fall short, a story is often found in our DNA that will provide clarity. Instead of waiting for sickness to occur, the clarity provided by a patient’s DNA can empower a Concierge physician to create a personalized plan for optimizing each patient’s health and longevity.”

Sykes concluded by saying, “Concierge Medicine Today believes that having your whole genome sequenced provides access to information that can empower people to improve their long term health and wellness. We support the use of Whole Genome Sequencing within Concierge Medicine programs and believe knowing more about your DNA will allow you to take steps towards living a healthier life.”

[1] http://www.techrepublic.com/article/chopra-health-care-is-about-to-get-a-lot-more-entrepreneurial-data-will-improve-personalized-health/

New Partnership Provides First-of-its-Kind Solutions for Transforming Genetic Data into Meaningful Information with Concierge Physicians & Sequencing.com at the Forefront of the Personal Genomics Revolution.

LOS ANGELES, CA | NOVEMBER 17, 2016 Sequencing.com, an online platform where people can securely store their genetic data and find apps that make genetic data understandable and useful, and Concierge Medicine Today (CMT), the premier publication in Concierge Medicine, have announced a partnership to help put Whole Genome Sequencing (WGS) technology into the hands of Concierge physicians.

Through this partnership, Concierge Medicine Physicians now have access to Whole Genome Sequencing services designed specifically for the practicing healthcare provider. The process is both non-invasive and simple: a saliva-collection kit is used to collect a saliva sample, which is then sent to a state-of-the-art laboratory that is a member of Sequencing.com’s Preferred Provider Network of genetic testing providers.

The laboratory isolates the person’s DNA from the saliva and sequences the person’s whole genome at 30X coverage. The massive amount of data generated by the lab is then securely transferred to Sequencing.com and made available to each physician. From there, the physician can use apps available at Sequencing.com to generate straightforward, actionable reports. The offer includes lifetime storage of the genetic data and two reports focused on wellness & longevity.

Concierge Medicine Today and Sequencing.com predict the widespread use of genome sequencing by [Concierge] physicians in daily clinical patient care. Previously available only in academic medical centers, this advanced healthcare technology provides the ability to predict and prevent disease. Due to decreasing costs and better understanding about how to make genetic data actionable, this advanced technology is moving out of academia and is now fully accessible to Concierge physicians.

Brandon Colby, MD, is a world leader in the field of Predictive Medicine, a groundbreaking medical specialty that combines comprehensive genetic testing with personalized prevention based upon your genes. Colby specializes in Personal Genomics and Anti-aging / Age Management Medicine and invented genetic technologies to personalize services and products to an individual's genes. He is the Founder and CEO of Sequencing.com and a good friend of Concierge Medicine Today.
Brandon Colby, MD, is a world leader in the field of Predictive Medicine, a groundbreaking medical specialty that combines comprehensive genetic testing with personalized prevention based upon your genes. Colby specializes in Personal Genomics and Anti-aging / Age Management Medicine and invented genetic technologies to personalize services and products to an individual’s genes. He is the Founder and CEO of Sequencing.com and a good friend of Concierge Medicine Today.

“The genetic revolution has already begun, and it is having far-reaching effects on healthcare right now,” said Brandon Colby, MD, a medical doctor, author of Outsmart Your Genes and Sequencing.com’s Founder and CEO. “Our knowledge of how to use this information is increasing at an exponential rate. What this means is that we can now start to integrate genetics into our everyday lives. With comprehensive genetic testing, we launch an innovative strategy against disease, attacking it before it even manifests. Whole Genome Sequencing, therefore, provides a new counter-offensive in our war against Alzheimer’s, cancer, heart disease, and many other diseases that have plagued our civilization for centuries. This is the most exciting, and potentially groundbreaking, medical development of this century.”

Editor-In-Chief, Michael Tetreault
Editor-In-Chief, Michael Tetreault

“DNA data with the continuous interaction and direction of a [Concierge] physician ushers in a healthcare utopia. In this way, it simplifies decision making using insights obtained from each person’s genetic data” said Michael Tetreault, Editor of Concierge Medicine Today.

“Genetic technology has reached the point where the cost of conducting comprehensive genetic testing [ie. Whole Genome Sequencing] for hundreds of preventable diseases at a single time is now affordable,” said Catherine Sykes, CEO, and Publisher of the national trade publication. “After years of thoughtful consideration, careful research and review, countless hours of dialogue with various physicians and technology companies, we encourage Concierge Medicine Physicians to make personal genomic data information available to patients so that they can start to understand their makeup, learn more about their individual genome and predictors and begin to use these insights to improve their lives.”

J. Catherine Sykes serves as the CEO/Publisher of Concierge Medicine Today (CMT)
J. Catherine Sykes serves as the CEO/Publisher of Concierge Medicine Today (CMT)

“Anything that moves us toward the realization of better outcomes using data and evidence-based medicine gets a green light by Concierge Medicine Today,” says Sykes. “Whole Genome Sequencing provides the data needed for Concierge physicians to be able to integrate personalized precision medicine into their practice.”

To learn more about Whole Genome Sequencing, visit: www.GeneticConciergeMedicine.com

About Sequencing.com:

Sequencing.com’s first-of-its-kind HIPAA-compliant platform allows people to obtain meaning and value from their genes. The platform includes an App Market with dozens of apps that empower individuals, researchers, bioinformaticians and healthcare professionals to tap into genetic data for deep and rich insights. It is a one-stop-shop that collates and organizes available genetic-based apps into a single online marketplace.

Sequencing.com’s platform is fully compatible with all genetic data formats and technologies, including Whole Genome Sequencing, exome sequencing, microarrays, and genealogy-focused DNA tests. Data generated by almost any genetic data can be stored and made useful at Sequencing.com including genetic tests offered by Illumina, BGI, Thermo Fisher, GeneDx, Ambry Genetics, Helix, National Geographic, Ancestry.com and 23andMe.

2016-cmt-logoAbout Concierge Medicine Today:

Concierge Medicine Today (CMT) is a news organization and the Concierge Medicine industry’s oldest national trade publication for the Concierge Medicine and Membership Medicine marketplaces. Its website is the online destination for businesses, consumers, physicians, legislators, researchers and other stakeholders to learn about the history of this industry, various business aspects of the marketplace, trends, breaking news and more that drives the conversation that Concierge Medicine and free market healthcare delivery is creating on a national and international level.

Click here to PURCHASE This MP3 ...Concierge Medicine Today recently released their Position Statement on Whole Genome Sequencing.

For more information, visit: www.GeneticConciergeMedicine.com.

NEWS: Concierge Medicine Today Expands Pharmacogenomic Application with Collaboration from Molecular Diagnostics company, Admera Health.

FOR IMMEDIATE RELEASE
Media Contact: Michael Tetreault, Editor | Tel. (770) 455-1650 ext 151 | editor@ConciergeMedicineToday.com

A new partnership equips Concierge Medicine and Direct Primary Care physicians with the most comprehensive pharmacogenomics testing, PGxOne™ Plus, allowing physicians to predict how patients will respond to drug therapy based on their individual genetic makeup.

admera-health-logoNOVEMBER 15, 2016 | South Plainfield, NJ – Molecular Diagnostics company Admera Health and Concierge Medicine Today (CMT), the premier publication in Concierge Medicine, announced a partnership to provide the simple, cost-effective, one-time pharmacogenomics test, PGxOneTM Plus. PGxOneTM Plus results can help predict how patients will respond to drug therapy for eleven therapeutic areas including psychiatry, pain management and cardiology.

Leveraging Next Generation Sequencing (NGS) technology, this expanded 50-gene panel can detect nearly 200 different variants and provides recommendations for over 220 associated drugs. The recommendations include considering alternatives when specific drugs should be avoided, dosage adjustment information when available, use with caution, and normal response expected. The PGxOne™ Plus report also provides information related to drug-to-drug, drug-to-food, drug-to-alcohol and drug-to-laboratory test interactions that are relevant to a patient’s current medications. Thus, test results offer physicians a valuable tool for guiding effective treatment decisions and potentially reducing trial-and-error treatment selection and adverse drug events.

“Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions and understands that Concierge Medicine is the ideal mechanism for delivering the industry’s most comprehensive pharmacogenomics test,” said Brady Millican, Vice President, Admera Health. “We are excited about the opportunity to facilitate and administer the PGxOne Plus test program, working with Admera Health and partnering with Concierge Medicine Today as we support the Concierge Physicians they serve,” stated Jeff Knapp, Managing Partner, Next Health Solutions, LLC.

Concierge Medicine Today issued a statement of support recently for the use and appropriate application of pharmacogenomics testing under the guidance and direction of a physician.

J. Catherine Sykes serves as the CEO/Publisher of Concierge Medicine Today (CMT)
J. Catherine Sykes serves as the CEO/Publisher of Concierge Medicine Today (CMT)

“What would happen if physicians could begin making treatment recommendations based upon a patient’s genotype?” said Catherine Sykes, CEO/Publisher of Concierge Medicine Today. “Concierge Doctors are in the habit of spending an inordinate amount of time with their patients, many of whom have significant and serious health issues. What would happen if we intentionally connected [Concierge] physicians with new scientific technologies that could enable them to deliver better precision treatment recommendations and provide more accurate prescribing to their patients? We aim to find out.”

“Pharmacogenomics is vanguard science which allows physicians to target an individual with the very best personalized therapy based on their own genetic information,” said Zeil Rosenberg, M.D., Vice President, Medical Affairs, Admera Health. “Thanks to major advances in medicine and information by patients, this knowledge translates into clear and immediate clinical benefits.”

“This is an important next step in medicine,” said Sykes. “It is critical that patients and their advising physician(s) begin to learn more about a person’s individual genome. Medical science is advancing more rapidly than we’ve ever seen, outpacing what a physician can possibly know about adverse drug interactions based on genotype. There are tests available and becoming increasingly more affordable that determine how patients will respond to drug therapy for a number of therapeutic areas, including psychiatry, pain management and cardiology.”

Patients need only to be tested once, as genetic information does not change over time. Therefore, these results have lifetime utility. As hospitals implement clinical pharmacogenomics testing programs in the coming years, more physicians will be able to utilize this valuable information to guide drug management and provide better patient care.

special
Admera Health, Next Health Solutions Have Created A Special Offer Exclusively for Concierge Physicians … Learn More …

About Admera Health

Admera Health is an advanced molecular diagnostics company focused on personalized medicine, non-invasive cancer testing and digital health. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health fulfills unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next generation technology platforms and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. Frost and Sullivan recognized Admera Health with the 2016 North American Award for Technology Innovation. Admera Health was recently profiled on Worldwide Business with Kathy Ireland®. Watch the interview by clicking here.

About Concierge Medicine Today

Concierge Medicine Today (CMT) is a news organization and the Concierge Medicine industry’s oldest national trade publication for the Concierge Medicine and Membership Medicine marketplace. Its web site is the online destination for businesses, consumers, physicians, legislators, researchers and other stakeholders to learn about the history of this industry, various business aspects of the marketplace, trends, breaking news and more that drives the conversation that Concierge Medicine and free market healthcare delivery is creating on a national and international level.  For more information, visit: http://www.ConciergeMedicineToday.org

OFFICIAL POSITION, STATEMENT: Use and Application of Pharmacogenomics Inside Concierge Medicine

 Concierge Medicine Today supports Concierge Medicine Doctors in working with pharmacists and pharmacogenomic companies to develop clinical decision support tools that will assist and guide prescribers in the use of pharmacogenomic information. Concierge Medicine Today further supports them in preparing and distributing materials for patient education and beginning to frame institutional guidelines for pharmacogenomic implementation inside local hospitals and specialty offices.

Concierge Medicine Today (CMT) Issues Statement of Support For Use and Application of Pharmacogenomics Inside Concierge Medicine

“Comprehensive Pharmacogenomics is a powerful healthcare innovation. Concierge Medicine provides the ideal delivery model for the future of predictive medicine,” says trade publication, Concierge Medicine Today. “Used under the guidance and application of a Concierge Physician, these tests can have a predictive effect on patient treatment outcomes, find adverse interactions and help to manage prescription dosages. Comprehensive screenings with more than 50 well-established pharmacogenomic genes in a single, cost-effective test can provide medically actionable and clinically relevant data, allowing Concierge Physicians, to make a more informed and thoughtful treatment recommendation for the health and well-being of each patient. Concierge Medicine Today strongly supports use of this innovative testing.”

2016-cmt-logoNOVEMBER 8, 2016 | ATLANTA, GA – Concierge Medicine Today issued a statement of support for the use and appropriate application of Pharmacogenomics under the guidance and direction of a Physician. “Pharmacogenomics aims to predict how individual genetic variability impacts drug absorption, metabolism and activity,” said Catherine Sykes, CEO and Publisher of the national trade publication. “Concierge Medicine Physicians are the ideal delivery mechanism for this comprehensive testing.”

Pharmacogenomics is the combination of pharmacology and genomics. It involves the study of genetic variations that influence an individual’s response to specific drugs. Pharmacology is the part of science that studies how drugs work. Genomics is the study of a person’s genome including the interactions of those genes with each other and with the person’s environment. Just as decision aids now alert prescribers that the patient takes a supplement that may interact with a prescription, these tests would alert the physician and prescriber that the patient is a poor metabolizer of a particular drug. While one pharmacology treatment approach may work well for one individual, the same approach may not be effective or may cause adverse drug effects in other patients. The implementation of pharmacogenomics helps physicians make informed treatment decisions. This can lead to better patient outcomes by decreasing adverse drug events and by increasing the effectiveness of drugs using data, research, science and the analysis and interpretation of the data by a licensed Physician.

RELATED STORY
DOCPRENEUR PODCAST: Meet a “Membership” Pharmacy. Where Everyone Qualifies + Rx Is Made Affordable (Listen Here Now …)

The notion of individual genetic variability has long been accepted and promoted within both the scientific community and the healthcare industry. Advances in molecular testing, and completion of the mapping of the human genome, in particular, give credence to the fact that patients respond differently to medications based upon their individual genetic makeup. Such advancements brought about the concept of personalized medicine, the practice of using an individual’s genetic profile to guide decisions for the prevention, treatment, and diagnosis of disease. Correspondingly, a major problem in the managed care industry is the variability of drug efficacy from patient to patient. While some patients complain about lack of effectiveness, other patients suffer from adverse drug events (ADEs). Personalized medicine has the ability to alleviate the burden of individual genetic variability and the resulting varied drug responses across different patient populations. Patient non-adherence to medications as prescribed is a significant economic burden; the resulting estimated annual healthcare costs are close to $3 billion in the United States.[1] The benefits of pharmacogenomics testing to patient adherence are frequently overlooked. Patients fail to take their medications for a number of reasons, such as the general sense that the medications do not work and anxieties related to the possible side effects listed within drug labels. For the non-adherent subset of the patient population, pharmacogenomics testing can serve as positive reinforcement and incentive for patients. Pharmacogenomics test results provide personalized, actionable facts for patients.

“Pharmacogenomics is breakthrough, next generation science which allows Physicians to target an individual with the very best personalized therapy based on their own genetic information,” said Zeil Rosenberg, M.D., Vice President, Medical Affairs, Admera Health. “What was science fiction 10 years ago is here today, thanks to major advances in medicine and information sciences. With an increasing thirst for information by patients, this knowledge translates in clear and immediate clinical benefits.”

admera_health_laboratory_photoConcierge Medicine Today cautions that in order to make this information actionable for patients, a Physician must fully integrate pharmacogenomics into system-wide prescribing practices. After years of thoughtful consideration, careful research and review and countless hours of dialogue with various physicians and companies, we recommend Concierge Medicine Physicians begin to make personal genomic data information and tests available to patients. However, the type of test matters. There are a number of offerings in the marketplace with more to come in the years ahead as these tests become more mainstream. Comprehensive screenings with more than 50 well-established pharmacogenomic genes in a single, cost-effective test will be able to provide medically actionable and clinically relevant data, allowing Concierge Physicians and their patients to make more informed and thoughtful treatment decisions.[2]

“This is an important next step in medicine,” said Sykes. “It is critical that patients and their advising Physician(s) begin to learn more about a person’s individual genome. Medical science is advancing more rapidly than we’ve ever seen, outpacing what a Physician can possibly know about adverse drug interactions based on genotype. There are tests available and becoming increasingly more affordable that determine how patients will respond to drug therapy for a number of therapeutic areas, including psychiatry, pain management, and cardiology.”

Patients need only to be tested once, as genetic information does not change over time. Therefore, genetic testing results have lifetime utility. As hospitals roll out pharmacogenomics programs in the coming years, patients will likely undergo tests for genetic variants known to play a role in the metabolism of a drug their Physician plans to prescribe.

As genetic testing becomes less expensive, more accessible, and generally, more common, Mark Dunnenberger, PharmD, Director of the Pharmacogenomics Program at NorthShore University HealthSystem in Evanston, IL. envisions in the near future that many patients’ medical records will already include a patient’s raw genetic data.[3]

RELATED STORY
DPC EDITOR: Successful “Docpreneurs” Know These 6 Things

“We need to build a system that allows us to pull out what we need at the moment that we need it and make clinical recommendations,” Dunnenberger said. “That changes the question from ‘Should I test you for this or for that?’ to ‘Let me go find that piece of data.’ That’s going to be really powerful if we build the informatics tools to support that.”

Pharmacogenomics is also integrating into EMRs. The NorthShore University HealthSystem is among just a handful in the nation which focuses exclusively on pharmacogenomics. NorthShore, with three hospitals, is the very first group to achieve Stage 7 on the HIMSS Analytics EMR Adoption Model. [4]

The American Medical Association (AMA) recently said of Pharmacogenomics, “Pharmacogenomics has the potential to provide tailored drug therapy based on genetically determined variation in effectiveness and side effects. This will mean:

  • More Powerful Medicines – Pharmaceutical companies will be able to produce therapies more targeted to specific diseases, maximizing therapeutic effects while decreasing damage to nearby healthy cells.
  • Better, Safer Drugs The First Time – Recovery time will go down and safety will go up as the likelihood of adverse reactions goes down or is eliminated, altogether.
  • More Accurate Methods Of Determining Appropriate Drug Dosages – Current methods of basing dosages on weight and age will be replaced with dosages based on a person’s genetics –how well the body processes the medicine and the time it takes to metabolize it.[5]

 Concierge Medicine Today supports Concierge Medicine Doctors in working with pharmacists and pharmacogenomic companies to develop clinical decision support tools that will assist and guide prescribers in the use of pharmacogenomic information. Concierge Medicine Today further supports them in preparing and distributing materials for patient education and beginning to frame institutional guidelines for pharmacogenomic implementation inside local hospitals and specialty offices.

Concierge Medicine Today encourages Concierge Medicine Physicians and the provider community to work with local pharmacists to lead the clinical application of pharmacogenomics. Collaborating together, as part of a safe, effective, and cost-efficient medication practice. Furthermore, to prepare all Concierge Medicine Physicians and staff to provide Pharmacogenomics testing and recommendations, Concierge Medicine Today calls on more State Associations, colleges of pharmacy and the Board of Pharmacy Specialties (BPS) to include curriculum about this growing field.

“What would happen if Physicians were able to begin making treatment recommendations based upon a patient’s genotype?” notes Sykes. “Concierge Doctors are in the habit of spending an inordinate amount of time with their patients, many of whom have significant and serious health concerns. What would happen if we intentionally connected [Concierge] physicians with new scientific technologies that could enable them to deliver more high precision treatment recommendations and provide more accurate prescribing to their patients? We aim to find out.”

Finally, Concierge Medicine Today believes, as do pharmacy organizations, that pharmacogenomics is primed for continued growth.

About Concierge Medicine Today

Concierge Medicine Today (CMT) is a news organization and the Concierge Medicine industry’s oldest national trade publication for the Concierge Medicine and Membership Medicine marketplace. Its web site is the online destination for businesses, consumers, physicians, legislators, researchers and other stakeholders to learn about the history of this industry, various business aspects of the marketplace, trends, breaking news and more that drives the conversation that Concierge Medicine and free market healthcare delivery is creating on a national and international level. For more information, visit: http://www.ConciergeMedicineToday.org

Sited Sources

Concierge Medicine Today Statement of Support For Quality Scores of Hospitals and Surgeons based on Medical Performance and Evidence-Based Medical Outcomes.

The core of the score should be a set of clinically driven, scientifically valid and weighted calculations about quality indicators that pertain to patients who are having surgery, finding a physician or visiting a hospital. ~Concierge Medicine Today

CMT, Official Position Statement ... Download PDF (Oct. 25, 2016)
CMT, Official Position Statement … Download PDF (Oct. 25, 2016)

ATLANTA, GA | FOR IMMEDIATE RELEASE | OCTOBER 25, 2016 – Concierge Medicine Today, a news organization and the Concierge Medicine industry’s oldest national trade publication for the Concierge Medicine and Private Medicine marketplace, issued a statement, noting, “Anyone seeking medical care, along with their referring Physician, should have access to a Quality Score [a simple, three-digit number] that individually measures their local hospital facilities, and surgeons, at the Procedure Level.”

According to MPIRICA Health, a Washington-based healthcare quality transparency company that scores hospitals and surgeons based on actual outcomes for specific surgeries, “Quality Scores should be designed as an objective comparison of facilities and physicians, so it is essential that the quality measurements upon which the score is based are themselves objective, and that the underlying data is adjusted to account for providers who take on higher-risk cases.”

RELATED STORY
MD² Expands, Granting Access to Two New World-Class Medical Institutions

Outcomes-based scoring is quite complex. The data on readmissions and patient mortality inside a hospital require no subjective interpretation, the data on complications however, is not as clearly documented. This is due to recording complications that require individual judgment. Coders, healthcare professionals and their patients may differ in their interpretation of events. As a result, complications may be recorded differently across facilities (or even by different coders within the same facility). Furthermore, even if codings were consistent, the codes themselves do not always separate a mild complication (like a simple infection) from a serious one that requires greater medical attention (like sepsis). Therefore, a time-tested, peer-reviewed methodology to account for complications must be integrated into Surgery Quality Scores.

CLICK HERE TO GET YOUR LOCAL AREA Hospital/Facility and Physician/Surgeon Quality Score ... Based On Data/Evidence, not reviews or subjective referrals ...
CLICK HERE TO GET YOUR LOCAL AREA Hospital/Facility and Physician/Surgeon Quality Score … Based On Data/Evidence, not reviews or subjective referrals …

Editor-In-Chief, Michael Tetreault
Editor-In-Chief, Michael Tetreault

“Concierge Medicine Today (CMT) is committed to transparency and the availability of information for patients to make informed decisions about their medical care” says Michael Tetreault, Editor of Concierge Medicine Today. “To accomplish this goal, objective quality measurements consisting of a set of clinically driven, scientifically valid and weighted calculations about quality indicators that matter to patients who are choosing a physician for their family, having surgery or need hospital care, must be simple to understand, objective, reliable, and complete. People deserve to have access to accurate information, especially when it concerns their health. Simply searching the web in today’s convoluted environment leads to inaccurate assumptions, misinterpretations, harms reputations and undermines the confidence that patients have in their physicians and local medical facilities they trusted.”

Tetreault adds, “It should take into consideration all of the important things that you should think about when planning for surgery and wrap them into a single performance score. The components of the Quality Score should also factor in and weigh important things like: Am I going to be in a hospital for a prolonged length of stay? What are my risks of complications? What are my chances of the ultimate poor outcome: death?”

Based on currently available data that are reported by hospitals, key measurements critical for evaluating quality should include: mortality; re-admissions; and complications.

CMT continues to support health care professionals and their patients in promoting and advocating for the transparency of information and trust that comes with having clinically driven, scientifically valid and weighted calculations pertaining to quality and making that information available and accessible to patients in a simple to understand format.

2016-cmt-logoAbout Concierge Medicine Today

Concierge Medicine Today (CMT) is a news organization and the Concierge Medicine industry’s oldest national trade publication for the Concierge Medicine and Private, Membership Medicine marketplace. Its web site is the online destination for businesses, consumers, physicians, legislators, researchers and other stakeholders to learn about the history of this industry, various business aspects of the marketplace, trends, breaking news and more that drives the conversation that Concierge Medicine and free market healthcare delivery is creating on a national and international level.  For more information, visit: http://www.ConciergeMedicineToday.org.

Doctor Evidence CMO Advocates Evidence-Based Medicine At Concierge Medicine Assembly, 2016 in ATLANTA, GA

Dr. Tom Price at the CMT Assembly (Atlanta, GA) speaking with Concierge Medicine Physicians. Source: Concierge Medicine Today; The DPC Journal
U.S. Congressman Tom Price, MD, Member of the Congressional Healthcare Caucus, Chairman of the House Committee on the Budget and Member of the House Committee on Ways and Means, was the Keynote Speaker at the Concierge Medicine Assembly in Atlanta, GA in August of 2015 and again at the CMT Assembly in 2016. Credit: Concierge Medicine Today/THE DPC JOURNAL, Aug 2016

SANTA MONICA, Calif., Aug. 11, 2016 /PRNewswire/ — Doctor Evidence CMO, Todd Feinman, will participate in two panels on the role of technology in bringing Evidence-Based Medicine (EBM) to improve physician efficiency and patient outcomes at the Concierge Medicine Assembly in Atlanta, Georgia, on August 12th and 13th, 2016.

J. Catherine Sykes serves as the CEO/Publisher of Concierge Medicine Today (CMT)
J. Catherine Sykes serves as the CEO/Publisher of Concierge Medicine Today (CMT)

Doctor Evidence (DRE) has more than a decade of experience in rigorous evidence-based medical methodologies and technologies which search, find and catalogue relevant data from peer-reviewed content, including clinical papers, conference proceedings, abstracts, and drug label data from the U.S. and Europe into user-friendly, relational databases. Dr. Feinman, who co-founded Doctor Evidence in 2004, helped develop one of the first Hospitalist programs in Southern California. As a Hospitalist and Medical Director for a large, independent physician association, Feinman realized that there were no accurate and user-friendly technologies that would enable him, or others, to use the data found in clinical studies to determine the most effective test or treatment for specific patient populations.

Dr. Todd Feinman
Dr. Todd Feinman,  Founder and CMO, DOCTOR EVIDENCE and a 2015 & 2016 Concierge Medicine Today (CMT) Faculty Member.

“Personalized application of evidence-based decisions should be the norm, and our company provides the technology to access the most up-to-date, patient-specific evidence for a given therapeutic area or intervention, so that physicians and patients can decide together the most effective course of treatment,” says Feinman. “Concierge doctors, known to be innovative and patient-centered care, are in a unique position to take advantage of the growing number of personalized data resources matched to patient profiles and preferences, including the Doctor Evidence technologies, to improve patient care.”

Utilizing DRE’s integrated, dynamic platform, doctors and patients can view underlying data being considered for the patient’s various treatment options and compare efficacy and safety of those treatments. These capabilities enable physicians and patients to engaged in shared decision-making with individualized patient preferences to determine true value-based care outcomes. This is a powerful tool to improving the use of evidence-based medicine at the point-of-care and improve patients’ outcomes.

“This is where Concierge Medicine really sets itself apart,” says Catherine Sykes, CEO/Publisher of Concierge Medicine Today at their annual 2016 Concierge Medicine Assembly held in Atlanta, GA last weekend, August 12-13, 2016.

DRE is launching new digital health applications that democratize enterprise-class solutions to the benefit of individual patients. DRE’s technology will allow patients and doctors to precisely match individual patient characteristics to evidence-based suggested therapies—resulting in improved outcomes.

The DRE platforms have proven valuable to global stakeholders across the healthcare ecosystem, including life-sciences companies, global academic institutions, pharmacy benefit managers, evidence-based practice centers, and leading healthcare providers in the marketplace.

About Doctor Evidence:  Doctor Evidence, LLC, founded in 2004, is a leader in technological solutions for evidence-based medicine with a mission to provide stakeholders across the healthcare ecosystem with the most timely and relevant medical evidence and related analytics to make and inform the best clinical decisions. Using its proprietary Digital Outcome Conversion (DOC™) platform and its rigorous methodology of extracting clinical data from static sources, including published studies and epidemiological databases, and creating dynamic, scientifically-curated data hubs which is pooled and analyzed to support the development of evidence-based clinical practice guideline recommendations, systematic reviews, and health technology assessments. For more information on Doctor Evidence innovations, please visit http://www.drevidence.com

SOURCE Doctor Evidence

Related Links

http://www.drevidence.com